Department of Pharmaceutical Chemistry, University of California-San Francisco, 1700 4th Street, San Francisco, CA 94158-2558, USA.
Biochemistry. 2010 Dec 7;49(48):10267-76. doi: 10.1021/bi101540g. Epub 2010 Nov 12.
Molecular biology now dominates pharmacology so thoroughly that it is difficult to recall that only a generation ago the field was very different. To understand drug action today, we characterize the targets through which they act and new drug leads are discovered on the basis of target structure and function. Until the mid-1980s the information often flowed in reverse: investigators began with organic molecules and sought targets, relating receptors not by sequence or structure but by their ligands. Recently, investigators have returned to this chemical view of biology, bringing to it systematic and quantitative methods of relating targets by their ligands. This has allowed the discovery of new targets for established drugs, suggested the bases for their side effects, and predicted the molecular targets underlying phenotypic screens. The bases for these new methods, some of their successes and liabilities, and new opportunities for their use are described.
分子生物学如今已完全主导药理学,以至于人们很难回想起仅仅一代人以前,该领域的情况还大不相同。为了了解当今的药物作用机制,我们通过药物作用的靶点来对其进行描述,而新药的研发则基于靶点的结构和功能。直到 20 世纪 80 年代中期,信息通常都是逆向流动的:研究人员从有机分子入手,寻找靶点,通过配体而非序列或结构来关联受体。最近,研究人员又回到了这种基于化学的生物学观点,采用系统和定量的方法,通过配体来关联靶点。这使得人们发现了现有药物的新靶点,揭示了其副作用的基础,并预测了表型筛选的分子靶点。本文描述了这些新方法的基础、部分成功和缺陷,以及它们的新应用机会。